Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

Similar articles for PubMed (Select 23206294)

1.

Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI).

Malm H, Artama M, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague I, Sourander A.

BMC Psychiatry. 2012 Dec 4;12:217. doi: 10.1186/1471-244X-12-217.

2.

Prenatal smoking exposure and the risk of psychiatric morbidity into young adulthood.

Ekblad M, Gissler M, Lehtonen L, Korkeila J.

Arch Gen Psychiatry. 2010 Aug;67(8):841-9. doi: 10.1001/archgenpsychiatry.2010.92.

PMID:
20679592
3.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Malm H, Klaukka T, Neuvonen PJ.

Obstet Gynecol. 2005 Dec;106(6):1289-96.

PMID:
16319254
4.

Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age.

Grzeskowiak LE, Gilbert AL, Sørensen TI, Olsen J, Sørensen HT, Pedersen LH, Morrison JL.

Ann Epidemiol. 2013 Nov;23(11):681-7. doi: 10.1016/j.annepidem.2013.08.005. Epub 2013 Oct 7.

PMID:
24113367
5.

Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia.

Colvin L, Slack-Smith L, Stanley FJ, Bower C.

CNS Drugs. 2012 Jul 1;26(7):e1-14. doi: 10.2165/11634190-000000000-00000.

6.

Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT.

Br J Clin Pharmacol. 2008 Apr;65(4):600-6. Epub 2007 Oct 22.

7.

Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.

Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B.

Am J Psychiatry. 2012 Nov;169(11):1165-74. doi: 10.1176/appi.ajp.2012.11111721.

PMID:
23128923
8.

Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors.

Grzeskowiak LE, Gilbert AL, Morrison JL.

J Clin Psychopharmacol. 2012 Oct;32(5):615-21. doi: 10.1097/JCP.0b013e31826686bc.

PMID:
22926594
9.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
10.

Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.

Gur TL, Kim DR, Epperson CN.

Psychopharmacology (Berl). 2013 Jun;227(4):567-82. doi: 10.1007/s00213-013-3115-8. Epub 2013 May 17. Review.

11.

Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.

Knickmeyer RC, Meltzer-Brody S, Woolson S, Hamer RM, Smith JK, Lury K, Gilmore JH.

Neuropsychopharmacology. 2014 Oct;39(11):2611-21. doi: 10.1038/npp.2014.114. Epub 2014 May 20.

PMID:
24837031
12.

Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality.

Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, Gissler M, Nørgaard M, Nielsen RB, Zoega H, Valdimarsdóttir U.

JAMA. 2013 Jan 2;309(1):48-54. doi: 10.1001/jama.2012.153812.

PMID:
23280224
13.

Finnish Prenatal Study of Bipolar Disorders (FIPS-B): overview, design and description of the sample.

Chudal R, Sucksdorff D, Suominen A, Lehti V, Hinkka-Yli-Salomäki S, Huttunen J, Ristkari T, Gissler M, McKeague IW, Brown AS, Sourander A.

Nord J Psychiatry. 2014 Apr;68(3):169-79. doi: 10.3109/08039488.2013.789073. Epub 2013 May 13.

PMID:
24627962
14.

Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.

El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H.

Arch Gen Psychiatry. 2012 Jul;69(7):706-14. doi: 10.1001/archgenpsychiatry.2011.2333.

PMID:
22393202
15.

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.

Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernández S, Botet F, Gelabert E, Subirà S, Plaza A, Valdés M, Martin-Santos R.

J Affect Disord. 2011 Dec;135(1-3):208-15. doi: 10.1016/j.jad.2011.07.022. Epub 2011 Sep 3.

PMID:
21890210
16.

Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study.

Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C.

BMJ. 2013 Apr 19;346:f2059. doi: 10.1136/bmj.f2059.

17.

No association between prenatal exposure to psychotropics and intelligence at age five.

Eriksen HL, Kesmodel US, Pedersen LH, Mortensen EL.

Acta Obstet Gynecol Scand. 2015 May;94(5):501-7. doi: 10.1111/aogs.12611. Epub 2015 Mar 17.

PMID:
25711407
18.

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.

J Clin Psychiatry. 2004 Feb;65(2):230-7.

PMID:
15003078
19.

Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.

Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M.

JAMA. 2013 Apr 24;309(16):1696-703. doi: 10.1001/jama.2013.2270.

PMID:
23613074
20.

Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.

Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M.

BMJ. 2015 Apr 17;350:h1798. doi: 10.1136/bmj.h1798. Erratum in: BMJ. 2015;350:h2235.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk